Arcus Biosciences

1. Casdatifan Ph3 interimMid-2026Casdatifan Ph3 interim, Mid-2026, major
2. Casdatifan / eVOLVE-RCC02 Ph3 readout2H 2026Casdatifan / eVOLVE-RCC02 Ph3 readout, 2H 2026, major
3. AB102 MRGPRX2 antagonist corporate update3Q 2026AB102 MRGPRX2 antagonist corporate update, 3Q 2026, routine
4. PEAK-1 / PEAK-20 enrollment doneYear-end 2026PEAK-1 / PEAK-20 enrollment done, Year-end 2026, notable
5. I&I portfolio MRGPRX2 antagonist trialLate 2026 / Early 2027I&I portfolio MRGPRX2 antagonist trial, Late 2026 / Early 2027, routine
6. ARC-20 cohorts cas+axitinib trial start4Q 2026ARC-20 cohorts cas+axitinib trial start, 4Q 2026, notable
7. Quemliclustat Ph3 topline1H 2027Quemliclustat Ph3 topline, 1H 2027, major

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.